Interim position emission tomography-computed tomography during multimodality treatment of locally advanced esophageal cancer: a scoping review.
Esophageal cancer (EC)
FDG
PET-CT
interim
prognostic value
Journal
Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
26
11
2022
accepted:
27
06
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
Among cancers, esophageal cancer (EC) has one of the highest incidences and mortality in Asia. As recognized in many national guidelines, functional imaging performed with position emission tomography is recommended for patients with locally advanced disease. This review evaluated evidence for the use of fluorodeoxyglucose (FDG) interim positron emission tomography (PETint) in bimodality (chemoradiation) and trimodality (chemoradiation followed by surgery) management of locally advanced esophageal cancer (LAEC), with a focus on its prognostic and predictive value. The MEDLINE database was searched from January 1, 2001, to January 1, 2022, as part of a scoping review. References of selected articles were manually checked to identify other articles meeting the inclusion criteria; only original articles were included, and reviews, guidelines, letters, editorials, and case reports were excluded. A total of 63 articles were included in this review. PET-computed tomography (PET-CT) is recognized as having a significant role in the assessment of treatment response. Studies on the predictive PETint suggest that it has a certain value, particularly for early response. Identification of poor responders or nonresponders soon after commencement of multimodality treatment allows for treatment modification. The scoping review indicated variable utility for the prognostic value of PETint. There is a need to improve its accuracy, which can likely be achieved through greater standardization of measurements and reporting and testing as well as combination with other promising measures of response to residual disease.
Sections du résumé
Background
UNASSIGNED
Among cancers, esophageal cancer (EC) has one of the highest incidences and mortality in Asia. As recognized in many national guidelines, functional imaging performed with position emission tomography is recommended for patients with locally advanced disease. This review evaluated evidence for the use of fluorodeoxyglucose (FDG) interim positron emission tomography (PETint) in bimodality (chemoradiation) and trimodality (chemoradiation followed by surgery) management of locally advanced esophageal cancer (LAEC), with a focus on its prognostic and predictive value.
Methods
UNASSIGNED
The MEDLINE database was searched from January 1, 2001, to January 1, 2022, as part of a scoping review. References of selected articles were manually checked to identify other articles meeting the inclusion criteria; only original articles were included, and reviews, guidelines, letters, editorials, and case reports were excluded.
Results
UNASSIGNED
A total of 63 articles were included in this review. PET-computed tomography (PET-CT) is recognized as having a significant role in the assessment of treatment response. Studies on the predictive PETint suggest that it has a certain value, particularly for early response. Identification of poor responders or nonresponders soon after commencement of multimodality treatment allows for treatment modification.
Conclusions
UNASSIGNED
The scoping review indicated variable utility for the prognostic value of PETint. There is a need to improve its accuracy, which can likely be achieved through greater standardization of measurements and reporting and testing as well as combination with other promising measures of response to residual disease.
Identifiants
pubmed: 37711778
doi: 10.21037/qims-22-1306
pii: qims-13-09-6280
pmc: PMC10498200
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6280-6295Informations de copyright
2023 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-22-1306/coif). The authors have no conflicts of interest to declare.
Références
Radiat Oncol. 2019 Feb 4;14(1):27
pubmed: 30717809
Thorac Cancer. 2015 Nov;6(6):687-94
pubmed: 26557905
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2003-2008
pubmed: 31350957
Cancer Radiother. 2005 May;9(3):152-60
pubmed: 16023043
Anticancer Res. 2017 Aug;37(8):4189-4194
pubmed: 28739705
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1345-55
pubmed: 23715903
Br J Cancer. 2006 Nov 6;95(9):1174-9
pubmed: 17024121
Clin Nucl Med. 2014 Oct;39(10):862-7
pubmed: 25140549
Crit Rev Oncol Hematol. 2016 Nov;107:128-137
pubmed: 27823640
J Am Coll Surg. 2008 May;206(5):879-86; discussion 886-7
pubmed: 18471715
Ann Surg. 2016 Nov;264(5):831-838
pubmed: 27741010
Br J Radiol. 2012 Sep;85(1017):e694-701
pubmed: 22337686
Am J Surg. 2002 Sep;184(3):279-83
pubmed: 12354600
J Clin Oncol. 2003 Feb 1;21(3):428-32
pubmed: 12560430
Semin Radiat Oncol. 2013 Jan;23(1):10-5
pubmed: 23207042
Lancet Oncol. 2007 Sep;8(9):797-805
pubmed: 17693134
EJNMMI Res. 2014 Mar 07;4(1):12
pubmed: 24602385
Dis Esophagus. 2017 Feb 1;30(2):1-7
pubmed: 27001344
Ann Surg. 2006 Apr;243(4):472-8
pubmed: 16552197
Mol Imaging Biol. 2002 Jul;4(4):301-10
pubmed: 14537121
Anticancer Res. 2017 Oct;37(10):5837-5843
pubmed: 28982909
Ann Surg. 2009 Dec;250(6):888-94
pubmed: 19953708
J Gastrointest Cancer. 2017 Mar;48(1):42-49
pubmed: 27604122
J Nucl Med. 2019 Nov;60(11):1553-1559
pubmed: 30877177
J Nucl Med. 2010 Dec;51(12):1863-9
pubmed: 21078796
Surgery. 2017 Oct;162(4):836-845
pubmed: 28711321
BMC Med Imaging. 2017 Jan 5;17(1):1
pubmed: 28056868
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):998-1009
pubmed: 31987972
Dis Esophagus. 2012 Jan;25(1):40-7
pubmed: 21595776
J Clin Oncol. 2004 Mar 1;22(5):900-8
pubmed: 14990646
Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60
pubmed: 15464463
Ann Surg. 2001 Mar;233(3):300-9
pubmed: 11224616
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1002-1007
pubmed: 30055238
Trials. 2021 May 17;22(1):345
pubmed: 34001287
Ann Surg. 2020 Feb;271(2):245-256
pubmed: 31188203
J Thorac Oncol. 2017 Jan;12(1):121-128
pubmed: 27569732
Ann Oncol. 2002 Mar;13(3):361-8
pubmed: 11996465
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):471-7
pubmed: 22381904
Ann Oncol. 2010 Oct;21 Suppl 7:vii294-9
pubmed: 20943631
Ann Oncol. 2019 Jan 1;30(1):34-43
pubmed: 30475943
Clin Nucl Med. 2011 Oct;36(10):860-6
pubmed: 21892034
Dis Esophagus. 2008;21(2):151-8
pubmed: 18269651
J Clin Oncol. 2010 Nov 1;28(31):4714-21
pubmed: 20876421
Br J Surg. 2014 Dec;101(13):1702-11
pubmed: 25351460
Eur J Nucl Med Mol Imaging. 2009 May;36(5):735-44
pubmed: 19096843
BMC Cancer. 2018 Oct 20;18(1):1006
pubmed: 30342494
Cancer Chemother Pharmacol. 2016 Apr;77(4):723-31
pubmed: 26891957
Nucl Med Commun. 2016 Sep;37(9):947-55
pubmed: 27145438
Int J Clin Exp Med. 2015 Jul 15;8(7):10947-55
pubmed: 26379889
Eur J Surg Oncol. 2004 Jun;30(5):544-50
pubmed: 15135484
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Cancer. 2007 Jan 1;109(1):125-34
pubmed: 17146785
JAMA Surg. 2015 Jun;150(6):555-62
pubmed: 25902198
Cancer Res Treat. 2013 Mar;45(1):22-30
pubmed: 23613667
Cancer. 2009 Nov 15;115(22):5184-92
pubmed: 19685531
Chin Med J (Engl). 2022 Feb 9;135(5):584-590
pubmed: 35143424
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):171-9
pubmed: 22660205
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883
pubmed: 31319389
Eur J Cancer. 2015 Nov;51(17):2545-52
pubmed: 26321501
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1053-9
pubmed: 15964705
Strahlenther Onkol. 2015 Feb;191(2):141-52
pubmed: 25163419
Radiother Oncol. 2008 Dec;89(3):278-86
pubmed: 18701180
Acta Oncol. 2015 Jun;54(6):909-15
pubmed: 25417733
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):477-85
pubmed: 23371374
Oncology. 2016;90(2):97-102
pubmed: 26771676
Crit Rev Oncol Hematol. 2021 Nov;167:103466
pubmed: 34508841
Anticancer Res. 2017 Feb;37(2):859-864
pubmed: 28179343
Ann Oncol. 2013 May;24(5):1262-6
pubmed: 23247658
Ann Surg. 2011 Jan;253(1):56-63
pubmed: 21233607
Radiother Oncol. 2017 Nov;125(2):200-212
pubmed: 29029833
Ann Surg. 2013 Jul;258(1):66-76
pubmed: 23470576
Ann Thorac Surg. 2016 Oct;102(4):1132-9
pubmed: 27319990
J Thorac Oncol. 2021 Feb;16(2):310-317
pubmed: 33307192
J Nucl Med. 2011 Aug;52(8):1189-96
pubmed: 21764790
Am J Clin Oncol. 2007 Aug;30(4):377-88
pubmed: 17762438
Eur J Cancer. 2007 Jun;43(9):1385-91
pubmed: 17512192
Ann Nucl Med. 2014 May;28(4):295-303
pubmed: 24474598
Clin Nucl Med. 2020 Jan;45(1):38-43
pubmed: 31714278
Dig Liver Dis. 2019 Jun;51(6):887-893
pubmed: 30630738
J Thorac Oncol. 2019 Jul;14(7):1156-1171
pubmed: 30999111
Ann Thorac Surg. 2013 Nov;96(5):1820-5
pubmed: 23895888
BMC Cancer. 2020 Mar 6;20(1):194
pubmed: 32143580